Literature DB >> 33430818

Case Report of a pathologically confirmed vascular parkinsonism with early cognitive impairment and Behavioral disturbance.

Shouzi Zhang1, Yuanyuan Wang2, Lixin Liu3, Li Zhang3, Li Ma3, Haiyan Wu3, Xuelin He3, Mingwei Zhu2, Luning Wang2, Fan Mei4.   

Abstract

BACKGROUND: Vascular Parkinsonism(VaP) is defined as parkinsonism resulting from cerebral vascular disease(CVD), with presence of variable motor and non-motor signs that are corroborated by clinical, anatomic or imaging findings of cerebrovascular disease. Overlapping syndromes with mixed pathologies make VaP difficult to distinguish from primary neurodegenerative parkinsonism.To understand the clinical and pathological features of VaP,we report a case of autopsy confirmed vascular Parkinsonism that was clinical misdiagnosed as idiopathic Parkinson's disease.Clinical features include early mixed symptoms of dementia,behavioral disturbance and parkinsonism that were similar to Dementia with lewy Body(DLB) and Parkinson disease Dementia(PDD). CASE
PRESENTATION: A 84-year-old man presented progressive parkinsonism with prominent postural instability, gait impairment, pseudobulbar, early cognitive impairment, irritability, hallucination, urinary symptoms and poor responsiveness to dopaminergic drugs. He was clinically diagnosed as Parkinson disease(PD). In the post-mortem study, we examined Aβ and phospho-tau as pathological biomarker for Alzheimer's disease(AD), α-synucleing in medulla, pons and midbrain for PD and DLB. Hematoxylin and eosin staining in cerebral cortex, cerebellum and brainstem examines vascular pathological changes and microvascular lesion.Neither Lewy bodies in the substantia nigra ,locus ceruleus and cerebrumnor accumulation of Aβ, neurofibrillary tangles were noted. Instead, there were many cerebral infarctions and widespread arteriosclerosis in the brain. The final brain autopsy supported a diagnosis of VaP not PD.
CONCLUSIONS: This case of pathologically confirmed VaP misdiagnosed as idiopathic PD suggested that we must be vigilant about the possibility of VaP for patients with parkinsonisms, cognitive impairments, early behavioral and psychological symptoms,imaging performances of cerebral small vessel disease and other vascular damages.

Entities:  

Keywords:  Cerebral small vessel disease (CSVD); Parkinson's disease(PD); Vascular dementia(VaD); Vascular parkinsonism(VaP)

Year:  2021        PMID: 33430818      PMCID: PMC7798293          DOI: 10.1186/s12883-020-02038-y

Source DB:  PubMed          Journal:  BMC Neurol        ISSN: 1471-2377            Impact factor:   2.474


  21 in total

Review 1.  An updated diagnostic approach to subtype definition of vascular parkinsonism - Recommendations from an expert working group.

Authors:  Ivan Rektor; Nicolaas I Bohnen; Amos D Korczyn; Viktoria Gryb; Hrishikesh Kumar; Milica G Kramberger; Frank-Erik de Leeuw; Zvezdan Pirtošek; Irena Rektorová; Ilana Schlesinger; Jaroslaw Slawek; Peter Valkovič; Branislav Veselý
Journal:  Parkinsonism Relat Disord       Date:  2017-12-29       Impact factor: 4.891

2.  Leucoaraiosis, nigrostriatal denervation and motor symptoms in Parkinson's disease.

Authors:  Nicolaas I Bohnen; Martijn L T M Müller; Natalia Zarzhevsky; Robert A Koeppe; Christopher W Bogan; Michael R Kilbourn; Kirk A Frey; Roger L Albin
Journal:  Brain       Date:  2011-06-08       Impact factor: 13.501

3.  Cerebral microbleeds and risk of incident dementia: the Framingham Heart Study.

Authors:  José R Romero; Alexa Beiser; Jayandra J Himali; Ashkan Shoamanesh; Charles DeCarli; Sudha Seshadri
Journal:  Neurobiol Aging       Date:  2017-03-06       Impact factor: 4.673

4.  Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study.

Authors:  Kurt A Jellinger
Journal:  Acta Neuropathol       Date:  2003-02-19       Impact factor: 17.088

Review 5.  Vascular parkinsonism: a review of the precision and frequency of the diagnosis.

Authors:  Thomas Foltynie; Roger Barker; Carol Brayne
Journal:  Neuroepidemiology       Date:  2002 Jan-Feb       Impact factor: 3.282

6.  123I-MIBG cardiac uptake, smell identification and 123I-FP-CIT SPECT in the differential diagnosis between vascular parkinsonism and Parkinson's disease.

Authors:  J Navarro-Otano; C Gaig; A Muxi; F Lomeña; Y Compta; M T Buongiorno; M J Martí; E Tolosa; F Valldeoriola
Journal:  Parkinsonism Relat Disord       Date:  2013-11-05       Impact factor: 4.891

7.  Inverse relationship between cerebrovascular lesions and severity of lewy body pathology in patients with lewy body diseases.

Authors:  Estifanos Ghebremedhin; Albert Rosenberger; Udo Rüb; Mario Vuksic; Tzeggai Berhe; Heike Bickeböller; Rob A I de Vos; Dietmar R Thal; Thomas Deller
Journal:  J Neuropathol Exp Neurol       Date:  2010-05       Impact factor: 3.685

8.  Incidence of Brain Infarcts, Cognitive Change, and Risk of Dementia in the General Population: The AGES-Reykjavik Study (Age Gene/Environment Susceptibility-Reykjavik Study).

Authors:  Sigurdur Sigurdsson; Thor Aspelund; Olafur Kjartansson; Elias F Gudmundsson; Maria K Jonsdottir; Gudny Eiriksdottir; Palmi V Jonsson; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer
Journal:  Stroke       Date:  2017-08-01       Impact factor: 7.914

9.  Space and location of cerebral microbleeds, cognitive decline, and dementia in the community.

Authors:  Jie Ding; Sigurður Sigurðsson; Pálmi V Jónsson; Gudny Eiriksdottir; Osorio Meirelles; Olafur Kjartansson; Oscar L Lopez; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer
Journal:  Neurology       Date:  2017-05-03       Impact factor: 9.910

10.  Life span pigmentation changes of the substantia nigra detected by neuromelanin-sensitive MRI.

Authors:  Yue Xing; Abdul Sapuan; Rob A Dineen; Dorothee P Auer
Journal:  Mov Disord       Date:  2018-11-13       Impact factor: 10.338

View more
  1 in total

1.  Therapeutic Effects of Quetiapine and 5-HT1A Receptor Agonism on Hyperactivity in Dopamine-Deficient Mice.

Authors:  Yukiko Ochiai; Masayo Fujita; Yoko Hagino; Kazuto Kobayashi; Ryoichi Okiyama; Kazushi Takahashi; Kazutaka Ikeda
Journal:  Int J Mol Sci       Date:  2022-07-04       Impact factor: 6.208

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.